News
Curated oncology headlines from reputable sources, ranked by importance with Claude Opus 4.7.
Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4
The Prostate Cancer Working Group 4 (PCWG4) has published updated consensus recommendations for clinical trial design and endpoint selection in prostate cancer, appearing in the Journal of Clinical Oncology. Building on the widely adopted PCWG3 framework from 2016, the new guidelines reflect the rapidly evolving treatment landscape that now includes PARP inhibitors, radioligand therapies, and nove…
VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor–Positive/HER2−/PIK3CA Wild-Type Advanced Breast Cancer
The Journal of Clinical Oncology has published full results from the phase 3 VIKTORIA-1 trial evaluating gedatolisib, a pan-class I PI3K/mTOR dual inhibitor, combined with fulvestrant with or without palbociclib in patients with hormone receptor-positive, HER2-negative advanced breast cancer harboring wild-type PIK3CA. This trial addresses a critical unmet need, as current PI3K-targeted agents suc…
[News] India introduces human papillomavirus vaccination
On February 28, 2026, Indian Prime Minister Narendra Modi launched the largest free human papillomavirus (HPV) vaccination campaign in history, aiming to immunize 11.5 million girls aged 14 across the country within 90 days. The vaccines will be administered free of charge at government-run health facilities, with the program subsequently integrated into India's Universal Immunisation Programme fo…
Reactivating p53 mutants selectively in patients
A commentary published in Cancer Cell highlights encouraging clinical results for rezatapopt, a small-molecule reactivator of mutant p53, recently reported in the New England Journal of Medicine. The tumor suppressor p53 is the most frequently mutated protein across human cancers and has long been considered an undruggable target, making any clinically meaningful progress against it a landmark eve…
Improving immunotherapy in solid tumors using FMT
A study published in Cell reports that fecal microbiota transplantation (FMT) significantly enhances the efficacy of first-line immune checkpoint inhibitors across multiple solid tumor types, including renal cell carcinoma, cutaneous melanoma, and non-small cell lung cancer. Clinical trial data showed that the benefit was achieved with an acceptable safety profile and appeared to be mediated by fu…
In what clinical settings are the MASAI trial results applicable?
Nature Reviews Clinical Oncology has published a commentary analyzing the clinical significance of the MASAI (Mammography Screening with Artificial Intelligence) trial, which is believed to be the first randomized controlled trial of AI-supported mammography interpretation to evaluate interval cancer rates as an endpoint. The Swedish trial demonstrated that using artificial intelligence to triage …
A 2026 update on myelodysplastic neoplasms: current state, challenges and future directions
A comprehensive review published in Nature Reviews Clinical Oncology provides a 2026 update on myelodysplastic neoplasms (MDS), a heterogeneous group of blood cancers characterized by ineffective blood cell production and a risk of progression to acute myeloid leukemia. The authors report that the epidemiological burden of MDS appears to be rising and detail recent advances in diagnosis, molecular…
Harnessing foundation models for digital pathology without re-training
Researchers have developed PRET, a training-free framework that adapts pathology foundation models to a wide range of clinical oncology tasks without the need for labeled data or model retraining. Published in Nature Cancer, the study demonstrates robust performance across pan-cancer diagnosis applications including cancer screening, tumor subtyping, tissue segmentation, and metastasis detection. …
Epigenetic fingerprints link early-onset colon and rectal cancer to pesticide exposure
A study published in Nature Medicine has identified epigenetic signatures linking pesticide exposure — particularly the herbicide picloram — to early-onset colorectal cancer in patients diagnosed before age 50. Researchers compared exposome traits between early-onset CRC patients and those diagnosed at age 70 or older, using epigenetic markers as molecular records of cumulative environmental expos…
No Survival Benefit With Mastectomy in Younger, High-Risk Breast Cancer
A prospective study has found that mastectomy does not significantly improve survival outcomes compared with less aggressive surgery in younger women with high-risk locoregionally advanced breast cancer. Despite mastectomy being the predominant surgical approach in this age group, the data suggest the more radical procedure offers no meaningful survival advantage. The findings challenge current cl…